Nektar Therapeutics | NKTR - Gross Profit On Sales


Nektar Therapeutics reported $21.81M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
ALKERMES USD 331.33M 7M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Baxter International USD 891M 314M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 44.1B 5B Jun/2026
Dr.Reddys Laboratories INR 41.78B 4.02B Jun/2026
Eisai JPY 153.41B 15.44B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
MacroGenics USD 11.24M 19.87M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Takeda JPY 688.84B 101.71B Mar/2026
Teva Pharmaceutical Industries USD 2.11B 547M Mar/2026
Xencor USD 21M 22.61M Sep/2025